Vertex Pharmaceuticals Incorporated VRTX has entered into an agreement to acquire ViaCyte, a private cellular therapy company, to accelerate the development of the VX-880 program in type I diabetes.
Vertex’s decision to double down on a pain program has delivered a phase 2 win. The biotech linked its NaV1.8 inhibitor VX-548 to statistically significant improvements in pain intensity in people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback